Are ONMD insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ONMD leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / ONMD / insiders

MXCT (34) BIAF (29) ISPC (30) NRC (67) ⌘ Pro Terminal →

OneMedNet Corp (Class A) (ONMD) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$4.22 -3.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.19

OneMedNet Corp (Class A) (ONMD) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $25.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ONMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ONMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, OneMedNet Corp (Class A) (NASDAQ: ONMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $4.22 (-3.43% 1D, market cap $25.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ONMD ranks #917 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ONMD compare to MXCT and BIAF in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ONMD carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MXCT (MaxCyte Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -27.1%, cap $164.1M) and BIAF (bioAffinity Technologies Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ONMD?

▼

Per ONMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001849380), OneMedNet Corp (Class A) generated $1.4M in revenue (+111.4% YoY), -$2.8M in net income, and -$7.5M in free cash flow against $2.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.19 (-0.81%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-14.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ONMD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (26/100 Composite)

🔍 WHY ONMD SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (31% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 38.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.02+18.2% Next Q

Q2 (-2Q)

Grade E$4.75-7.4% Next Q

Q3 (-1Q)

Grade E$4.40-4.1% Next Q

Current

Grade E$4.22-10.5% Hist 90D α

Trajectory: E (18) → E (26)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ONMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ONMD currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.49) and Max Pain ($4.43) forces dealer call-delta covering toward $24.15.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ONMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ONMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 26%NO 74%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ONMD Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ONMD)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ONMD. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ONMD)

✓Walkthrough of ONMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ONMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -59.81%▼ DESCENDING CHANNEL

2026-11-03O $4.37H $4.37L $4.22C $4.22VOL 61.1K

RES: $7.43SUP: $2.58SMA50: $5.49SMA200: $7.16

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ONMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ONMD Butterfly Map → + Track ONMD →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +111.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ONMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ONMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ONMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ONMD)

Health Care Rank #917 of 1015 ⚔️ MXCT vs ONMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ONMD vs. MXCT, BIAF, ISPC, NRC)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, OneMedNet Corp (Class A) (ONMD) ranks #917 by composite RQD confidence (26/100, grade E) and #816 by equity capitalization ($25.4M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with ONMD at 26/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ONMD ACTIVE OneMedNet Corp (Class A)	E	26/100	—	-30.0%	-35.0%	-3.43%	$25.4M	Benchmark Subject
MXCT MaxCyte Inc.	E	34/100	—	96.0%	-27.1%	-8.09%	$164.1M	/mxct-vs-onmd →
BIAF bioAffinity Technologies Inc.	E	29/100	—	—	-35.0%	-3.96%	$3.7M	/biaf-vs-onmd →
ISPC iSpecimen Inc.	E	30/100	—	11.2%	-35.0%	+4.19%	$2.1M	/ispc-vs-onmd →
NRC NRC Health	C+	67/100	44.8x	—	21.0%	+1.45%	$527.1M	/nrc-vs-onmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001849380 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OneMedNet Corp (Class A) (ONMD) reported GAAP revenue of $1.4M (+111.4% vs. FY2024 revenue of $643.0K , and +33.1% cumulative change since FY2023) , GAAP net income of -$2.8M, operating cash flow of -$7.5M, and free cash flow of -$7.5M (-7.3% YoY). On the balance sheet, ONMD closed FY2025 with $2.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.4M	-$2.8M	-$7.5M	-$7.5M	$2.2M	—
FY2024 (FY)	2024-12-31	$643.0K	-$10.1M	-$7.0M	-$7.0M	$3.7M	—
FY2023 (FY)	2023-12-31	$1.0M	-$33.8M	-$4.8M	-$4.8M	—	—

3. ONMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ONMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ONMD compare to MXCT and BIAF in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ONMD?

Where is ONMD trading relative to its 50-day, 200-day, and 52-week technical levels?

ONMD last traded at $4.22 (-3.43% on volume of 61,060 shares), positioning the stock -23.13% below its 50-day simple moving average ($5.49) and -41.06% below its 200-day simple moving average ($7.16). Across its 52-week range of $3.61 to $23.00, ONMD sits at the 3.1% percentile with a 14-day RSI of 38.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.69 to $4.75).

Direct Sub-Reports: ONMD RQD Cockpit ONMD 12M Forecast ONMD Earnings & Move ONMD Dividends & DRIP ONMD Insiders & 13F ONMD Whale Options ONMD Profit Sankey ONMD News & Why

ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ SEC XBRL & RQD VERIFIED

ONMD — OneMedNet Corp (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

OneMedNet Corp (Class A) (ONMD) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.22 (-3.43% 1D, market capitalization $25.4M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of -30.0%, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

— The profile confirms the sector as Health Care and the industry as Biotechnology: Commercial Physical & Biological Resarch, listed on NASDAQ, with a market capitalization of $0.0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), OneMedNet Corp (Class A) (ONMD) reported $1.4M in annual revenue (up from $643.0K in FY2024, +111.4% YoY) and -$2.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.0M revenue, -$33.8M net income) through FY2025, ONMD scaled operating cash flow to -$7.5M and free cash flow to -$7.5M, backed by $2.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.61 – $23.00 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks therefore cannot be mapped from the source data. The only sector-level context available is the Health Care classification and a Beta of 1.0.

Key Question #1: Can ONMD sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.4M and free cash flow of -$7.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is ONMD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ONMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for OneMedNet Corp (Class A) (ONMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ONMD Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 1d ago

OneMedNet Corp Estimates – NASDAQ:ONMD

TradingView report covering OneMedNet Corp (Class A) (ONMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Nigeria • 1d ago

Onemednet CFO Robert Golden sells $55,290 in company stock By Investing.com

Investing.com Nigeria report covering OneMedNet Corp (Class A) (ONMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 1d ago

A new partner will distribute OneMedNet’s de-identified U.S. medical data to drug companies worldwide.

Stock Titan report covering OneMedNet Corp (Class A) (ONMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Monday's Pre-Market Session - Mobile-health Network (NASDAQ:MNDR), DataME

Benzinga report covering OneMedNet Corp (Class A) (ONMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

OneMedNet 10% Owner Purchased Shares Worth Over $750K

TradingView report covering OneMedNet Corp (Class A) (ONMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Canada • 1d ago

OneMedNet director Thomas Kosasa invests $750,001 in common stock By Investing.com

Investing.com Canada report covering OneMedNet Corp (Class A) (ONMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Liquidia (NASDAQ:LQDA), Greenland Mines

Benzinga report covering OneMedNet Corp (Class A) (ONMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Canada • 1d ago

Onemednet CEO Aaron Green sells $47,762 in company stock By Investing.com

Investing.com Canada report covering OneMedNet Corp (Class A) (ONMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ONMD Bull vs. Bear Conversation Board — What's Your Call at $4.22?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ONMD 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $5.19 (+23.0%)

📌 Pinned Debate

A new partner will distribute OneMedNet's de-identified U.S. medical data to drug companies worldwide, a GREEN-flagged catalyst that co

The street is overcomplicating OneMedNet Corp (Class A) (ONMD). A new partner will distribute OneMedNet's de-identified U.S. medical data to drug companies worldwide, a GREEN-flagged catalyst that could open a revenue channel.. With an RQD score of 26/100 (E) and Forensic Balance Sheet at 8/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $4.56.

CapAlloc_Nerd 🐂 BULL

@MidwestValue Agree on the RQD 26/100 quality, though with 1.0 beta I'm scaling in with half-size at $4.22 and keeping dry powder in case we test $3.92.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $3.17 (-24.9%)

Spot @ $4.22

A -35% ROIC, negative FCF across three reported years, and an RQD score of 26 (Grade E) signal that the business is not currently self-

Careful chasing ONMD at $4.22. A -35% ROIC, negative FCF across three reported years, and an RQD score of 26 (Grade E) signal that the business is not currently self-funding.. Gross margin is -30.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $3.17 on multiple compression.